Suggested remit - To appraise the clinical and cost effectiveness of quizartinib within its marketing authorisation for treating relapsed or refractory FLT3-ITD-positive acute myeloid leukaemia.
Following on from information provided to NICE by the company in September 2019, the appraisal of Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1325
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- Daiichi Sankyo (quizartinib)
- Others
- Department of Health
- NHS England
- Welsh Government
- Patient carer groups
- Bloodwise
- Leukaemia CARE
- Professional groups
- Association of Cancer Physicians
- British Society for Haematology
- Cancer Research UK
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Pfizer (cytarabine, idarubicin) (confidentiality agreement signed)
- Accord Healthcare Ltd (cytarabine, etoposide, fludarabine, idarubicin, mitoxantrone) (confidentiality agreement not signed)
- Actavis (fludarabine) (confidentiality agreement not signed)
- Amgen (filgrastim)
- Hospira UK (cytarabine, fludarabine, filgrastim) (confidentiality agreement not signed)
- Napp Pharmaceuticals (cytarabine) (confidentiality agreement not signed)
- Sandoz (fludarabine, filgrastim) (confidentiality agreement not signed)
- Teva (fludarabine) (confidentiality agreement not signed)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
- National Cancer Research Institute
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 November 2022 | Discontinued. Following on from information provided to NICE by the company in September 2019, the appraisal of Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 18 October 2019 | Suspended. On 17 October 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for Quizartinib for treating relapsed or refractory acute myeloid leukaemia. Therefore, this appraisal has been suspended. NICE will continue to monitor any developments and will update stakeholders if the situation changes. |
| 26 September 2019 | Please note that following an update received from the company, the NICE appraisal committee discussion on Wednesday 2 October 2019 has been cancelled and will be rescheduled in due course. NICE will continue to monitor any development and further information regarding the timelines of this appraisal will be available once known. |
| 26 September 2019 | In progress. In progress |
| 12 April 2019 | Following an update from Daiichi Sankyo UK, the committee date for the appraisal of quizartinib for treating relapsed or refractory acute myeloid leukaemia has been rescheduled to 2 October 2019. |
| 09 November 2018 | Invitation to participate |
| 27 June 2018 - 25 July 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 05 December 2017 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual